Ristaben (Sitagliptin) 25 mg
DPP-4 inhibitor for adults with type 2 diabetes mellitus
Quick Facts About Ristaben
Key Takeaways About Ristaben
- Glucose-dependent action: Ristaben lowers blood sugar mainly when it is high, giving a low intrinsic risk of hypoglycaemia when used alone
- Renal-adjusted dosing: The 25 mg strength is designed for adults with severe renal impairment (eGFR < 30 mL/min) or end-stage renal disease on dialysis
- Once-daily tablet: Taken orally once a day with or without food, offering simple adherence compared with multi-dose regimens
- Serious but rare risks: Acute pancreatitis, severe hypersensitivity reactions, Stevens–Johnson syndrome, and bullous pemphigoid have been reported and require urgent medical attention
- Combination therapy: Ristaben is commonly added to metformin, sulfonylureas, thiazolidinediones, or insulin when blood sugar targets are not met on a single agent
What Is Ristaben and What Is It Used For?
Ristaben is an oral prescription medicine containing sitagliptin, a selective DPP-4 inhibitor used to improve blood glucose control in adults with type 2 diabetes mellitus. It is prescribed when diet, exercise and, where appropriate, other antidiabetic medicines do not provide sufficient control. The 25 mg tablet strength is intended specifically for patients with severely reduced kidney function.
Ristaben is a glucose-lowering medicine for adults with type 2 diabetes mellitus, a chronic metabolic disorder characterised by insulin resistance and a progressive decline in pancreatic beta-cell function. It was centrally authorised by the European Medicines Agency (EMA) following the same clinical development programme as sitagliptin (also marketed under other trade names), reflecting an established evidence base of phase III randomised trials and long-term outcome studies. According to the World Health Organization, type 2 diabetes accounts for more than 90% of all diabetes cases worldwide, affecting over 500 million adults globally.
The active substance sitagliptin belongs to a therapeutic class known as dipeptidyl peptidase-4 (DPP-4) inhibitors, also referred to as gliptins. These medicines improve glycaemic control by enhancing the body's own physiological response to eating a meal, without directly introducing insulin. This mechanism contributes to a favourable safety profile, particularly with respect to hypoglycaemia and weight neutrality, which makes sitagliptin a widely used option for older adults and patients in whom other therapies may be contraindicated.
Ristaben is approved for use in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control and when metformin is either not tolerated or contraindicated. More commonly, it is prescribed as add-on therapy in combination with metformin, sulfonylureas, thiazolidinediones (such as pioglitazone), or insulin, with or without metformin, when additional glucose lowering is required. It is not indicated for the treatment of type 1 diabetes or for the acute management of diabetic ketoacidosis.
How Ristaben Works
Under normal physiological conditions, the gut releases hormones called incretins after meals. The two main incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), stimulate the pancreas to release insulin in response to rising blood glucose and suppress glucagon release from the alpha cells. Both hormones are rapidly inactivated within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves them into inactive fragments. In type 2 diabetes, this short-lived incretin response is often blunted, contributing to postprandial hyperglycaemia.
Ristaben works by selectively and reversibly inhibiting DPP-4, thereby prolonging the circulating half-life of active GLP-1 and GIP. Clinical pharmacology studies show that sitagliptin increases active incretin concentrations two- to three-fold after a meal, resulting in enhanced glucose-dependent insulin secretion and reduced glucagon release. Because the effect is tightly glucose-dependent, insulin output falls as glucose levels normalise, which explains the low intrinsic risk of hypoglycaemia when Ristaben is used as monotherapy or with metformin.
In pooled analyses of randomised controlled trials, sitagliptin lowers glycated haemoglobin (HbA1c) by approximately 0.5–1.0 percentage points, with greater reductions observed in patients with higher baseline HbA1c. Fasting plasma glucose and postprandial glucose also decrease modestly. The cardiovascular safety of sitagliptin was demonstrated in the TECOS trial (Trial Evaluating Cardiovascular Outcomes with Sitagliptin), which enrolled more than 14,000 adults with type 2 diabetes and established clinical cardiovascular disease, showing non-inferiority versus placebo for major adverse cardiovascular events.
Sitagliptin is predominantly eliminated unchanged by the kidneys (approximately 79% of an oral dose is recovered in urine). In patients with severely reduced kidney function, the same dose would accumulate to higher plasma concentrations than intended. The Ristaben 25 mg tablet was developed to deliver an appropriate systemic exposure in adults with severe renal impairment and end-stage renal disease, preserving efficacy while minimising the risk of dose-related adverse effects.
What Should You Know Before Taking Ristaben?
Before starting Ristaben, discuss your full medical history with your doctor, including any allergic reactions, pancreatitis, kidney disease, or skin disorders. The medicine is not suitable if you are allergic to sitagliptin, and caution is required during pregnancy, in people with a history of pancreatitis, and when combined with insulin or sulfonylureas.
Ristaben is generally well tolerated, but like all medicines it carries specific risks that should be weighed against the expected benefits. Your doctor will assess your overall diabetes control, kidney function, liver function and comorbidities before prescribing, and will periodically reassess treatment. Understanding the contraindications, warnings and lifestyle considerations described below helps you use Ristaben safely and recognise rare but important side effects early.
Contraindications
You must not take Ristaben if:
- You are allergic (hypersensitive) to sitagliptin or to any of the other ingredients of the tablet
- You have previously experienced a serious hypersensitivity reaction to a DPP-4 inhibitor, including anaphylaxis, angioedema or exfoliative skin conditions
Ristaben is not a substitute for insulin and must never be used in patients with type 1 diabetes or during diabetic ketoacidosis. Tell your doctor before starting treatment if you have experienced any unexplained allergic symptoms with previous medicines.
Warnings and Precautions
Discuss the following conditions and circumstances with your doctor before taking Ristaben:
- History of pancreatitis: Acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising pancreatitis, has been reported with sitagliptin. Stop taking Ristaben and seek urgent medical attention if you develop severe, persistent abdominal pain that may radiate to the back, with or without vomiting
- Kidney disease: The Ristaben 25 mg strength is specifically adjusted for adults with severe renal impairment or those on dialysis. Kidney function should be assessed before initiation and periodically during treatment
- Combination with sulfonylureas or insulin: The risk of hypoglycaemia is considerably higher when Ristaben is added to these medicines. A dose reduction of the sulfonylurea or insulin may be needed
- Heart failure: Although sitagliptin itself has not been associated with an increased risk of heart failure in the TECOS trial, inform your doctor if you have established heart disease so that overall cardiovascular risk can be managed
- Skin lesions or ulcers: Diabetes predisposes to foot and skin complications. In addition, bullous pemphigoid — an autoimmune blistering skin disorder — has been reported with DPP-4 inhibitors and may require discontinuation
- Hypersensitivity reactions: Serious allergic reactions, Stevens–Johnson syndrome, and angioedema have been reported, sometimes within the first three months of treatment
Stop taking Ristaben and seek immediate medical help if you develop: severe and persistent abdominal pain with or without vomiting (possible pancreatitis); swelling of the face, lips, tongue or throat, difficulty swallowing or breathing (possible angioedema/anaphylaxis); widespread rash, blistering or peeling of the skin (possible Stevens–Johnson syndrome or bullous pemphigoid); or signs of severe hypoglycaemia such as confusion, seizures or loss of consciousness.
Pregnancy and Breastfeeding
There is limited human data on the use of sitagliptin during pregnancy. Animal studies have not shown direct harmful effects on reproduction at therapeutic doses, but the medicine should not be used during pregnancy as a precaution. Tight glycaemic control is essential during pregnancy, and insulin is the preferred treatment for pregnant women with type 2 diabetes because of its long-established safety record. If you become pregnant while taking Ristaben or plan to become pregnant, contact your doctor promptly.
It is not known whether sitagliptin is excreted in human breast milk, and animal studies have shown that it can pass into milk. Ristaben is not recommended during breastfeeding. If treatment is necessary, your doctor will discuss alternative antidiabetic regimens or the option of interrupting breastfeeding.
Driving and Using Machines
Ristaben itself has little or no influence on the ability to drive or operate machinery. However, certain side effects such as dizziness and drowsiness have been reported, which could impair these activities. More importantly, when Ristaben is combined with sulfonylureas or insulin, hypoglycaemia can affect alertness and reaction time. Patients should be aware of this risk, monitor their blood glucose appropriately, and avoid driving if they feel symptoms of low blood sugar.
Children and Adolescents
The safety and efficacy of Ristaben in children and adolescents below 18 years of age have not been established. It should not be used in this age group outside of carefully supervised clinical research settings.
Elderly Patients
No specific dose adjustment is required on the basis of age alone. However, elderly patients are more likely to have reduced kidney function, so renal assessment is important. If severe renal impairment is present, the Ristaben 25 mg strength is the appropriate choice. Clinical experience in patients over 75 years of age is more limited, so treatment should be individualised with careful monitoring.
How Does Ristaben Interact with Other Drugs?
Ristaben has a low overall interaction potential because sitagliptin is not substantially metabolised by cytochrome P450 enzymes. The most clinically relevant interactions involve additive hypoglycaemia risk with sulfonylureas or insulin, a modest increase in digoxin exposure, and a theoretical increase in angioedema risk with ACE inhibitors.
Always provide your doctor and pharmacist with a complete list of prescription medicines, over-the-counter products, herbal remedies and dietary supplements you take. Although sitagliptin rarely causes pharmacokinetic interactions, careful review of concomitant medications is essential, particularly in patients taking multiple diabetes treatments or medicines with narrow therapeutic windows.
Major Interactions
| Interacting Drug/Class | Effect | Recommendation |
|---|---|---|
| Sulfonylureas (e.g. glimepiride, glibenclamide) | Additive blood glucose lowering; markedly increased risk of hypoglycaemia | Consider reducing sulfonylurea dose when initiating Ristaben; monitor blood glucose closely |
| Insulin (all formulations) | Increased risk of hypoglycaemia, particularly at night | Insulin dose reduction of 10–20% may be required; intensified self-monitoring |
| Digoxin | Small increase in digoxin AUC (approximately 11%) and peak plasma concentration | No routine dose adjustment, but monitor patients at risk of digoxin toxicity |
| ACE inhibitors (e.g. enalapril, ramipril) | Possible increased risk of angioedema when used together | Counsel patients on symptoms of angioedema; weigh benefits and risks in susceptible individuals |
| Other antihyperglycaemic agents (SGLT2 inhibitors, GLP-1 receptor agonists) | Additive glucose-lowering effect; potentially useful combinations but risk of hypoglycaemia with other agents | Evaluate overall regimen; avoid overlap with GLP-1 receptor agonists as both target the incretin axis |
| Strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) in renal impairment | Minor increase in sitagliptin exposure; clinically relevant only in severe renal impairment | No dose adjustment required in most patients; monitor in combined severe renal impairment |
Minor and Theoretical Interactions
Sitagliptin is not a significant inhibitor or inducer of the common cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9, CYP1A2) at therapeutic concentrations. Clinical drug interaction studies with metformin, rosiglitazone, warfarin, oral contraceptives, simvastatin and cyclosporine have not shown clinically meaningful changes in exposure. This makes Ristaben a generally convenient partner in polypharmacy regimens typical of patients with long-standing type 2 diabetes.
Some case reports describe interactions with the combination of DPP-4 inhibitors and dual RAAS blockade (combining an ACE inhibitor with an angiotensin receptor blocker), with possible increases in angioedema risk. Routine laboratory monitoring of liver and kidney function during long-term treatment is appropriate, as is reassessment if the patient starts or stops any other regular medication.
Moderate alcohol consumption does not directly interact with sitagliptin. However, alcohol itself can affect blood glucose — initially raising it and later causing delayed hypoglycaemia — particularly when combined with sulfonylureas or insulin. Patients should consume alcohol in moderation, with food, and monitor their blood glucose after drinking.
What Is the Correct Dosage of Ristaben?
Ristaben 25 mg is taken once daily, with or without food. The 25 mg strength is the recommended dose for adults with severe renal impairment (creatinine clearance below 30 mL/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis. Patients with better kidney function typically require higher sitagliptin strengths (50 mg or 100 mg).
Ristaben is designed for simple, adherence-friendly dosing: one tablet per day, taken orally at roughly the same time each day. The tablet should be swallowed whole with water and must not be split or crushed. If you forget a dose, take it as soon as you remember on the same day; if you do not remember until the next day, skip the missed dose and continue with your regular schedule. Never take two doses in one day to make up for a missed one.
| Patient Group | Kidney Function (eGFR or CrCl) | Typical Daily Dose | Ristaben 25 mg Appropriate? |
|---|---|---|---|
| Normal or mildly reduced | ≥ 60 mL/min/1.73 m² | 100 mg once daily | No – higher strength required |
| Moderate renal impairment | 45 to < 60 mL/min/1.73 m² | 100 mg once daily | No – standard dose |
| Moderate renal impairment (lower range) | 30 to < 45 mL/min/1.73 m² | 50 mg once daily | No – 50 mg preferred |
| Severe renal impairment | < 30 mL/min/1.73 m² | 25 mg once daily | Yes |
| End-stage renal disease on dialysis | Haemodialysis or peritoneal dialysis | 25 mg once daily | Yes – may be given without regard to dialysis timing |
Adults
Standard Adult Dosing
The recommended dose of sitagliptin in adults with normal or mildly reduced kidney function is 100 mg once daily, taken with or without food. Ristaben 25 mg is not the appropriate strength for these patients; they should receive the 100 mg tablet. If sitagliptin is added to existing therapy with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to minimise hypoglycaemia risk.
Adults with Severe Renal Impairment or Dialysis
For adults with creatinine clearance less than 30 mL/min, including those on haemodialysis or peritoneal dialysis, the recommended dose is Ristaben 25 mg once daily. On haemodialysis days, the dose may be administered at any time relative to the dialysis session because sitagliptin is not appreciably removed by dialysis. Kidney function should be assessed before initiation and monitored periodically during treatment.
Children and Adolescents
Not Recommended Below 18 Years
Ristaben is not recommended for use in children and adolescents under 18 years of age, because the safety and efficacy of sitagliptin have not been adequately established in this population. Paediatric type 2 diabetes typically requires specialist management, usually with metformin and lifestyle intervention, and occasionally insulin.
Elderly
Dose Depends on Renal Function
In elderly patients, dosing is guided by estimated glomerular filtration rate (eGFR) rather than chronological age. Because kidney function frequently declines with age, Ristaben 25 mg may be the appropriate strength for many older adults, even in the absence of overt kidney disease. Clinical experience in patients aged over 75 years is more limited, and treatment should be individualised with caution.
Missed Dose
Take As Soon As You Remember Same Day
If you miss a dose of Ristaben, take it as soon as you remember on the same day. If it is already close to the time of your next scheduled dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a forgotten tablet, as this may increase the risk of side effects without additional benefit.
Overdose
Seek Medical Advice
If you take more Ristaben than prescribed, contact your doctor, a hospital emergency department, or your local poisons information service. In clinical studies, single doses up to 800 mg were generally well tolerated, with dose-dependent QT interval prolongation reported at very high exposures. Treatment of overdose is supportive and may include removal of unabsorbed drug from the gastrointestinal tract, clinical monitoring (including electrocardiogram), and treatment of any specific symptoms. Sitagliptin is only modestly removed by haemodialysis.
What Are the Side Effects of Ristaben?
Most patients tolerate Ristaben well. The most frequently reported side effects in clinical trials were headache, upper respiratory tract infections and nasopharyngitis. Hypoglycaemia is common when Ristaben is combined with a sulfonylurea or insulin. Rare but serious side effects include acute pancreatitis, severe hypersensitivity reactions, Stevens–Johnson syndrome and bullous pemphigoid, which require immediate medical attention.
Like all medicines, Ristaben can cause side effects, although not everyone experiences them. The frequency categories used below follow the European Medicines Agency convention, based on clinical trial and post-marketing surveillance data. Reporting any suspected side effect to your healthcare team — even if mild — helps to build a fuller picture of the medicine's safety in real-world use.
Stop taking Ristaben and contact emergency services or go to a hospital immediately if you experience: severe and persistent abdominal pain that may radiate to the back, with or without vomiting (possible pancreatitis); swelling of the face, lips, tongue or throat, difficulty swallowing or breathing, rapid heartbeat (possible anaphylaxis/angioedema); widespread skin rash with blistering or peeling (possible Stevens–Johnson syndrome or bullous pemphigoid); or severe hypoglycaemia with confusion, seizures or loss of consciousness.
Side Effects by Frequency
Very Common (affects more than 1 in 10 patients)
- Hypoglycaemia when Ristaben is used in combination with a sulfonylurea or insulin — symptoms include trembling, sweating, hunger, dizziness, and blurred vision
Common (affects up to 1 in 10 patients)
- Headache
- Upper respiratory tract infection (sore throat, cough, runny nose)
- Nasopharyngitis
- Osteoarthritis and pain in the arms or legs
- Nausea
- Decreased blood glucose (mild hypoglycaemia) in combination regimens
- Constipation
Uncommon (affects up to 1 in 100 patients)
- Dizziness
- Abdominal pain
- Diarrhoea
- Vomiting
- Decreased appetite
- Itching (pruritus)
- Drowsiness or somnolence
- Dry mouth
Rare (affects up to 1 in 1,000 patients) and Very Rare (post-marketing)
- Acute pancreatitis, including haemorrhagic and necrotising forms (rare but potentially fatal)
- Severe hypersensitivity reactions: anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis
- Stevens–Johnson syndrome (life-threatening skin reaction)
- Bullous pemphigoid (autoimmune blistering skin disorder)
- Acute renal failure, sometimes requiring dialysis
- Interstitial lung disease
- Severe joint pain
- Rhabdomyolysis (muscle breakdown)
Recognising Hypoglycaemia
When Ristaben is combined with a sulfonylurea or insulin, hypoglycaemia is the most clinically relevant adverse event. Early warning symptoms include sweating, trembling, hunger, pounding heartbeat and anxiety. Neuroglycopenic symptoms — confusion, slurred speech, drowsiness and seizures — can occur if blood glucose drops further. Treat early symptoms promptly with 15–20 g of fast-acting carbohydrate (such as glucose tablets, sugar-sweetened drinks or fruit juice), and recheck blood glucose after 15 minutes.
In severe hypoglycaemia with loss of consciousness, family members or carers should administer intramuscular or subcutaneous glucagon if available, and emergency services should be contacted immediately. Patients on insulin or sulfonylureas should carry a diabetes identification card, wear a medical-alert bracelet where available, and teach relatives how to respond to severe hypoglycaemia.
Reporting Suspected Side Effects
Reporting suspected adverse reactions helps regulators monitor the long-term safety of medicines. Patients and healthcare professionals are encouraged to report side effects to their national pharmacovigilance system — in the European Union via the national competent authority, in the United States via FDA MedWatch, and in the United Kingdom via the Yellow Card Scheme.
How Should You Store Ristaben?
Store Ristaben tablets below 30°C in the original blister pack to protect them from moisture. Refrigeration is not required. Keep the medicine out of sight and reach of children, never use tablets past the expiry date printed on the carton, and return any unused medicine to a pharmacy for safe disposal.
Ristaben tablets are moisture-sensitive and should remain in the original blister packaging until they are taken. The outer carton also protects against light. Typical storage recommendations, in line with the approved Summary of Product Characteristics, include:
- Store below 30°C (room temperature). Do not freeze and do not refrigerate
- Keep in the original blister pack to protect from moisture
- Do not use after the expiry date printed on the blister and carton. The expiry date refers to the last day of the month stated
- Keep out of sight and reach of children at all times, ideally in a locked medicine cabinet or high shelf
- Do not transfer tablets to pill boxes or other containers unless a pharmacist has specifically advised so, as this can reduce protection from moisture
Safe Disposal
Unused or expired Ristaben must not be disposed of in household waste or flushed down toilets or drains. Leftover medicine should be returned to a community pharmacy or local take-back scheme, which will arrange for environmentally safe destruction in accordance with national regulations. Proper disposal protects the environment from inadvertent release of pharmaceuticals into water supplies.
When travelling, carry Ristaben in its original packaging together with a copy of your prescription and, if crossing borders, a doctor's letter. Keep the medicine in your hand luggage, not in checked baggage where temperatures can be extreme. If crossing time zones, plan your dosing schedule with your diabetes team before travel to maintain once-daily administration without gaps or duplication.
What Does Ristaben Contain?
Each Ristaben 25 mg film-coated tablet contains sitagliptin (as sitagliptin phosphate monohydrate) as the active substance, together with standard pharmaceutical excipients in the tablet core and film coating. Ristaben is gluten-free; it does not contain clinically relevant amounts of lactose.
The composition of Ristaben is designed to deliver sitagliptin reliably into the bloodstream while maintaining tablet stability and acceptable taste and handling. The active ingredient is present as a phosphate salt (sitagliptin phosphate monohydrate), which provides improved solubility and stability compared with the free base. Each 25 mg tablet contains an amount of sitagliptin phosphate monohydrate equivalent to 25 mg of sitagliptin free base.
Active Ingredient
- Sitagliptin (as sitagliptin phosphate monohydrate) — 25 mg per film-coated tablet
Tablet Core Excipients
- Microcrystalline cellulose (E460) — bulking agent and disintegrant
- Calcium hydrogen phosphate, anhydrous (E341) — diluent
- Croscarmellose sodium (E468) — super-disintegrant to aid rapid tablet breakdown
- Magnesium stearate (E470b) — lubricant
- Sodium stearyl fumarate — lubricant
Film Coating Excipients
- Poly(vinyl alcohol)
- Macrogol 3350 (polyethylene glycol)
- Talc (E553b)
- Titanium dioxide (E171) — white pigment
- Iron oxide red (E172) and iron oxide yellow (E172) — colourants giving the tablet its pink appearance
Appearance and Packaging
Ristaben 25 mg tablets are pink, round, film-coated tablets with identification markings on one side. They are supplied in opaque aluminium/aluminium blister packs to protect against moisture and light. Pack sizes typically include 14, 28, 30, 56, 84 or 98 tablets, with smaller starter packs also available in some markets. Not all pack sizes may be marketed in every country.
Ristaben tablets contain sodium (from sodium stearyl fumarate) but in amounts that are considered "essentially sodium-free" by EMA standards (less than 1 mmol per tablet). Patients on strict sodium-restricted diets can use this medicine without concern. The medicine does not contain gluten, and the excipient quantities are not associated with clinically relevant reactions in patients with common food allergies.
Frequently Asked Questions About Ristaben
Ristaben (sitagliptin) is a prescription medicine used to improve blood glucose control in adults with type 2 diabetes mellitus. It can be prescribed as monotherapy when diet and exercise alone do not provide adequate control and when metformin is not suitable, or as add-on therapy to metformin, sulfonylureas, thiazolidinediones (such as pioglitazone), or insulin. The 25 mg strength is specifically intended for patients with severe renal impairment or those on haemodialysis or peritoneal dialysis.
Ristaben works by selectively inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down incretin hormones (GLP-1 and GIP) released from the gut after meals. By prolonging the activity of these incretins, sitagliptin increases glucose-dependent insulin secretion from the pancreas and suppresses glucagon release. Because the effect is glucose-dependent, Ristaben mainly acts when blood sugar is elevated, which contributes to its low intrinsic risk of hypoglycaemia when used alone.
The most frequently reported side effects in clinical trials were headache, upper respiratory tract infections, nasopharyngitis, and osteoarthritis. When Ristaben is combined with a sulfonylurea or insulin, hypoglycaemia becomes common. Rare but serious side effects include acute pancreatitis, severe hypersensitivity reactions (including anaphylaxis and Stevens–Johnson syndrome), bullous pemphigoid, and acute renal failure. Patients should report persistent severe abdominal pain, skin blistering or swelling of the face and throat immediately.
Ristaben 25 mg is the recommended sitagliptin dose for adults with severe renal impairment (creatinine clearance below 30 mL/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis. The tablet is taken once daily, with or without food, at roughly the same time each day. On dialysis days, the dose may be given without regard to the timing of dialysis. Patients with normal or mildly reduced kidney function generally require the higher 50 mg or 100 mg strengths of sitagliptin instead.
Ristaben used on its own carries a low risk of hypoglycaemia because it only stimulates insulin release when blood glucose is elevated. The risk increases significantly when Ristaben is combined with a sulfonylurea (such as glimepiride or glibenclamide) or with insulin. In these combinations, your doctor may reduce the dose of the sulfonylurea or insulin to minimise the risk. Symptoms of hypoglycaemia include sweating, trembling, hunger, dizziness and confusion, and should be treated promptly with a source of fast-acting sugar such as glucose tablets or a sugary drink.
Ristaben should generally not be used during pregnancy because there is limited human data on its safety in pregnant women. Insulin remains the preferred treatment for type 2 diabetes during pregnancy due to its long-established safety record. It is not known whether sitagliptin is excreted in human breast milk, and its use during breastfeeding is not recommended. Women of childbearing potential should discuss contraception and treatment plans with their doctor before starting Ristaben, and should contact their healthcare provider immediately if they become pregnant while on treatment.
Ristaben tablets should be stored below 30°C in the original blister pack to protect them from moisture. The medicine does not require refrigeration and must not be frozen. Keep the tablets out of sight and reach of children, ideally in a locked cupboard or high shelf. Do not use Ristaben after the expiry date printed on the carton, and do not dispose of unused medicine in household waste or wastewater — return expired or unused tablets to a pharmacy for safe disposal in accordance with local regulations.
References
- European Medicines Agency (EMA). Ristaben — Summary of Product Characteristics (SmPC) and European Public Assessment Report (EPAR). Available at: ema.europa.eu/en/medicines/human/EPAR/ristaben. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Sitagliptin — Prescribing Information. Originally approved 2006, current revision 2025.
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS). N Engl J Med. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352
- Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387-405. doi:10.1080/14740338.2018.1444027
- Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369. doi:10.1136/bmj.e1369
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl. 1):S1-S321.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024.
- World Health Organization (WHO). Global Report on Diabetes. Geneva: WHO; updated 2023.
- British National Formulary (BNF). Sitagliptin monograph. Current edition. BMJ Group and Pharmaceutical Press.
About the Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialists in endocrinology, diabetology, pharmacology and clinical medicine. Our content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines (EMA, FDA, ADA, EASD, NICE) and established medical standards. No commercial funding influences our content.
Every article undergoes a rigorous multi-step review: initial research by medical writers, clinical accuracy verification by specialist physicians, editorial review for clarity and accessibility, and final approval by the Medical Review Board before publication.
We prioritise Level 1A evidence from systematic reviews and randomised controlled trials. All medical claims are referenced to peer-reviewed sources or authoritative international guidelines. We declare no conflicts of interest.
Last medically reviewed: | Published: | Read our editorial standards